D.E. Shaw & Co
BIOR

D.E. Shaw & Co’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

D.E. Shaw & Co’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,053
Closed -$550K – 6160
2021
Q4 		$550K Buy
+1,053
New +$756K ﹤0.01% 4350
2021
Q3 		– Sell
-968
Closed -$864K – 5437
2021
Q2 		$864K Buy
+968
New +$740K ﹤0.01% 3665
2021
Q1 		– Sell
-177
Closed -$235K – 4608
2020
Q4 		$235K Buy
+177
New +$260K ﹤0.01% 3679

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co's BIOR Position: Q1 2022 in Review

D.E. Shaw & Co sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q1 2022, closing a stake of 1,053 shares — an estimated $550K sold.

D.E. Shaw & Co first reported a position in BIOR in Q4 2020 and held it in 3 quarters. The position peaked at $864K in Q2 2021. 51 funds tracked by Wall St. Rank hold BIOR as of Q1 2022.

  • D.E. Shaw & Co reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,053 Biora Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $550K.
  • D.E. Shaw & Co first reported a position in Biora Therapeutics, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • D.E. Shaw & Co's Biora Therapeutics, Inc. Common Stock position peaked at $864K in Q2 2021.
  • 51 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.